Health Condition 1: N00-N99- Diseases of the genitourinary system
Conditions
Interventions
Intervention1: Elagolix: dose 150 mg once a day orally
for three months
Intervention2: Elagolix 150 mg once day: Nil
Intervention3: Nil: Nil
Control Intervention1: Dienogest: Dose 2 mg once a day oral
Sponsors
University of Kashmir
Eligibility
Inclusion criteria
Inclusion criteria: Female patients aged 18 to 45 years Diagnosed with endometriosis clinical or USG based VAS pelvic pain score equal or greater than 4 Willing to undergo 3 months of treatment and follow up Provided written informed consent
Exclusion criteria
Exclusion criteria: Hormonal therapy or surgery for endometriosis in past 3 months Significant hepatic renal or bone disease Pregnancy or lactation Other pelvic pathologies mimicking endometriosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Decrease in pelvic pain score VASTimepoint: Three months after treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of LifeTimepoint: three months after treatment;Uterine Volume Endometrioma Volume Fluid Cyst volumeTimepoint: three months after treatment;CA 125 levelsTimepoint: Three months after Treatment | — |
Countries
India
Contacts
Public ContactDrGhulam Nabi Bader
Department of Pharmaceutical Sciences University of kashmir
Outcome results
None listed